1,128 assets in Non-Small Cell Lung Carcinoma

Therapeutic assets addressing Non-Small Cell Lung Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
ql2107 Non-Small Cell Lung Carcinoma	Qilu Pharmaceutical Co., Ltd.	P3	B (56)
Relatlimab Non-Small Cell Lung Carcinoma	Regeneron Pharmaceuticals	P3	B (56)
Si-B001 Non-Small Cell Lung Carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P2/3	B (56)
Talazoparib Non-Small Cell Lung Carcinoma	Pfizer	P3	B (56)
Taletrectinib Non-Small Cell Lung Carcinoma	Innovent Biologics (Suzhou) Co. Ltd.	P3	B (56)
Telisotuzumab Adizutecan Non-Small Cell Lung Carcinoma	AbbVie	P2/3	B (56)
XENON Non-Small Cell Lung Carcinoma	Xemed LLC	P2	B (56)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Non-Small Cell Lung Carcinoma	Kura Oncology, Inc.	P2	CCC (55)
Abiraterone Non-Small Cell Lung Carcinoma	MacroGenics	P2	CCC (55)
Balstilimab Non-Small Cell Lung Carcinoma	Immune Oncology Research Institute	P2	CCC (55)
Bio 300 Non-Small Cell Lung Carcinoma	Memorial Sloan Kettering Cancer Center	P2	CCC (55)
Botensilimab Non-Small Cell Lung Carcinoma	Immune Oncology Research Institute	P2	CCC (55)
Disitamab Non-Small Cell Lung Carcinoma	Sun Yat-sen University	P2	CCC (55)
Enzalutamide Non-Small Cell Lung Carcinoma	MacroGenics	P2	CCC (55)
Etrumadenant Non-Small Cell Lung Carcinoma	Gilead Sciences	P2	CCC (55)
Hydroxychloroquine Non-Small Cell Lung Carcinoma	Abramson Cancer Center at Penn Medicine	P2	CCC (55)
Lurbinectedin Non-Small Cell Lung Carcinoma	Fox Chase Cancer Center	P2	CCC (55)
mk-3475 Non-Small Cell Lung Carcinoma	Merck Sharp & Dohme LLC	P3	CCC (55)
Naptumomab Estafenatox Non-Small Cell Lung Carcinoma	NeoTX Therapeutics Ltd.	P2	CCC (55)
Recombinant Ephb4-Hsa Fusion Protein Non-Small Cell Lung Carcinoma	University of Southern California	P2	CCC (55)
Regorafenib Non-Small Cell Lung Carcinoma	Neonc Technologies, Inc.	P2	CCC (55)
Ribociclib Non-Small Cell Lung Carcinoma	Novartis Pharmaceuticals	P1/2	CCC (55)
Tucatinib Non-Small Cell Lung Carcinoma	Jonathan Riess	P2	CCC (55)
(1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil 1:4 Non-Small Cell Lung Carcinoma	AstraZeneca	P3	CCC (54)
azd7789 Non-Small Cell Lung Carcinoma	AstraZeneca	P1/2	CCC (54)
Bms-986504 Non-Small Cell Lung Carcinoma	Bristol-Myers Squibb	P2/3	CCC (54)
Calderasib Non-Small Cell Lung Carcinoma	Merck Sharp & Dohme LLC	P3	CCC (54)
Cobimetinib Non-Small Cell Lung Carcinoma	Cancer Research UK	P2/3	CCC (54)
eik1001 Non-Small Cell Lung Carcinoma	Eikon Therapeutics	P2/3	CCC (54)
Erythromycin Non-Small Cell Lung Carcinoma	Qianfoshan Hospital	P3	CCC (54)
Hafnium Oxide Non-Small Cell Lung Carcinoma	M.D. Anderson Cancer Center	P1/2	CCC (54)
hs-20093 Non-Small Cell Lung Carcinoma	Hansoh BioMedical R&D Company	P3	CCC (54)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Met (Met Proto-Oncogene, Hepatocyte Growth Factor (Hgf) Receptor, Hgfr, Scatter Factor (Sf) Receptor, Hgf/Sf Receptor, Receptor Tyrosine-Protein Kinase C-Met, Papillary Renal Cell Carcinoma 2, Rccp2)] And Anti-[Homo Sapiens Egfr (Epidermal Growth Factor Receptor, Receptor Tyrosine-Protein Kinase Erbb-1, Erbb1, Her1, Her-1, Erbb)], Homo Sapiens Monoclonal Antibody, Bispecific Non-Small Cell Lung Carcinoma	Betta Pharmaceuticals Co., Ltd.	P2	CCC (54)
Immunoglobulin G4 [221-Proline], Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Sg001 ?4-Chain), Disulfide With Human Monoclonal Sg001 ?-Chain, Dimer Non-Small Cell Lung Carcinoma	CSPC Megalith Biopharmaceutical Co.,Ltd.	P3	CCC (54)
Indocyanine Green Non-Small Cell Lung Carcinoma	St. Joseph's Healthcare Hamilton	P2	CCC (54)
Neratinib Non-Small Cell Lung Carcinoma	Convalife (Shanghai) Co., Ltd.	P2	CCC (54)
Ociperlimab Non-Small Cell Lung Carcinoma	Novartis Pharmaceuticals	P3	CCC (54)
rc148 Non-Small Cell Lung Carcinoma	RemeGen Co., Ltd.	P3	CCC (54)
Repotrectinib Non-Small Cell Lung Carcinoma	Bristol-Myers Squibb	P3	CCC (54)
Setidegrasib Non-Small Cell Lung Carcinoma	Astellas Pharma Global Development, Inc.	P3	CCC (54)
Shr-A2009 Non-Small Cell Lung Carcinoma	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P3	CCC (54)
sy-5007 Non-Small Cell Lung Carcinoma	Shouyao Holdings (Beijing) Co. LTD	P3	CCC (54)
Uliledlimab Non-Small Cell Lung Carcinoma	TJ Biopharma Co., Ltd.	P2/3	CCC (54)
Upifitamab Rilsodotin Non-Small Cell Lung Carcinoma	Mersana Therapeutics	P1/2	CCC (54)
Adbelimumab Non-Small Cell Lung Carcinoma	Jiangsu HengRui Medicine Co., Ltd.	P2	CCC (53)
ak146d1 for Non-Small Cell Lung Carcinoma	Akeso	P2	CCC (53)
alk202 Non-Small Cell Lung Carcinoma	Shanghai Allink Biotherapeutics Co., Ltd.	P2	CCC (53)
Atirmociclib Non-Small Cell Lung Carcinoma	Pfizer	P2	CCC (53)
b1962 Non-Small Cell Lung Carcinoma	Tasly Biopharmaceuticals Co., Ltd.	P2	CCC (53)
Bevacizumab Biosimilar - Shanghai Henlius Biotech Non-Small Cell Lung Carcinoma	Henan Cancer Hospital	P2	CCC (53)

Showing 251 to 300 of 1,128 assets

PreviousPage 6 of 23Next